可洛米分 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "可洛米分" in Chinese language version.

refsWebsite

Global rank Chinese rank

32doi.org

2^nd place

23^rd place

27nih.gov

4^th place

5^th place

14web.archive.org

1^st place

14books.google.com

3^rd place

8^th place

10semanticscholar.org

11^th place

332^nd place

3drugs.com

399^th place

208^th place

3archive.org

6^th place

4^th place

3worldcat.org

5^th place

12^th place

2handle.net

102^nd place

492^nd place

2nytimes.com

7^th place

31^st place

2usada.org

low place

1fda.gov

447^th place

581^st place

1sciencedirect.com

149^th place

292^nd place

1lww.com

2,769^th place

1,362^nd place

1uptodate.com

3,771^st place

4,225^th place

1espacenet.com

800^th place

1,214^th place

1hhpronline.org

low place

1latimes.com

22^nd place

110^th place

1sfgate.com

166^th place

570^th place

1psu.edu

207^th place

628^th place

1wada-main-prod.s3.amazonaws.com

low place

archive.org

World Health Organization. Stuart MC, Kouimtzi M, Hill SR , 编. WHO Model Formulary 2008. World Health Organization. 2009: 385–386. ISBN 9789241547659. hdl:10665/44053 .
Haskell SG. Selective estrogen receptor modulators. Southern Medical Journal. May 2003, 96 (5): 469–76. PMID 12911186. S2CID 40607634. doi:10.1097/01.SMJ.0000051146.93190.4A.
Maximov PY, McDaniel RE, Jordan VC. Tamoxifen Goes Forward Alone. Tamoxifen. Milestones in Drug Therapy. Springer. 2013: 31–46. ISBN 978-3-0348-0663-3. ISSN 2296-6064. doi:10.1007/978-3-0348-0664-0_2.

books.google.com

Ghumman S. Principles and Practice of Controlled Ovarian Stimulation in ART. Springer. 2015: 65. ISBN 9788132216865. （原始内容存档于2016-12-27）.
Becker KL. Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. 2001: 1206–. ISBN 978-0-7817-1750-2.
Cameron R, Feuer G, de la Iglesia F. Drug-Induced Hepatotoxicity. Springer Science & Business Media. 6 December 2012: 565–. ISBN 978-3-642-61013-4.
Runnebaum B, Rabe T. Gynäkologische Endokrinologie und Fortpflanzungsmedizin: Band 1: Gynäkologische Endokrinologie. Springer-Verlag. 17 April 2013: 88–. ISBN 978-3-662-07635-4.
Roche V, Zito WS, Lemke T, Williams DA. Foye's Principles of Medicinal Chemistry. Wolters Kluwer Health. 29 July 2019: 3010–. ISBN 978-1-4963-8587-1.
Zhang X. Estrogen Receptor and Breast Cancer: Celebrating the 60th Anniversary of the Discovery of ER. Springer. 16 October 2018: 153–. ISBN 978-3-319-99350-8.
Maximov PY, McDaniel RD, Jordan VC. Tamoxifen: Pioneering Medicine in Breast Cancer. Springer Science & Business Media. 23 July 2013: 34–. ISBN 978-3-0348-0664-0.
Harper MJ. Pharmacological Control of Reproduction in Women. Jucker E (编). Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Birkhäuser. 2013-12-21: 69–. ISBN 978-3-0348-7065-8.
Hormones and Breast Cancer. Elsevier. 2013-06-25: 13–. ISBN 978-0-12-416676-9.
Analytical Profiles of Drug Substances and Excipients. Academic Press. 1998-03-20: 113–. ISBN 978-0-08-086120-3. （原始内容存档于2017-11-05）.
Howell A, Jordan VC. Adjuvant Antihormone Therapy. Craig JV (编). Estrogen Action, Selective Estrogen Receptor Modulators And Women's Health: Progress And Promise. World Scientific. 2013: 229–254. ISBN 978-1-84816-959-3. doi:10.1142/9781848169586_0010.
Arturo Bris and Christos Cabolis, Corporate Governance Convergence Through Cross-Border Mergers The Case of Aventis 互联网档案馆的存檔，存档日期2014-04-21., Chapter 4 in Corporate Governance and Regulatory Impact on Mergers and Acquisitions: Research and Analysis on Activity Worldwide Since 1990. Eds Greg N. Gregoriou, Luc Renneboog. Academic Press, 2007-07-26
Strauss JF, Barbieri RL. Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. 2013-09-13: 518–. ISBN 978-1-4557-2758-2. （原始内容存档于2017-11-05）.
Hormones and Breast Cancer. Elsevier. 2013-06-25: 13–. ISBN 978-0-12-416676-9. （原始内容存档于2017-11-05）.

doi.org

Kim MJ, Byeon JY, Kim YH, Kim SH, Lee CM, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY, Choi CI. Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites. Archives of Pharmacal Research. March 2018, 41 (3): 347–353. PMID 29516347. S2CID 4034257. doi:10.1007/s12272-018-1005-7.
Yilmaz S, Yilmaz Sezer N, Gönenç İM, İlhan SE, Yilmaz E. Safety of clomiphene citrate: a literature review. Cytotechnology. April 2018, 70 (2): 489–495. PMC 5851961 . PMID 29159661. doi:10.1007/s10616-017-0169-1.
Mikkelson TJ, Kroboth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertility and Sterility. September 1986, 46 (3): 392–396. PMID 3091405. doi:10.1016/S0015-0282(16)49574-9.
Dickey RP, Holtkamp DE. Development, pharmacology and clinical experience with clomiphene citrate. Human Reproduction Update. 1996, 2 (6): 483–506. PMID 9111183. doi:10.1093/humupd/2.6.483 .
Rodriguez KM, Pastuszak AW, Lipshultz LI. Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opinion on Pharmacotherapy. August 2016, 17 (11): 1561–7. PMC 5009465 . PMID 27337642. doi:10.1080/14656566.2016.1204294.
Kintz, Pascal; Gheddar, Laurie. Interest of hair tests and supplement tests to discriminate a tail end of a doping regimen from a supplement contamination in case of challenging an anti-doping rule violation. VII. Case example with clomiphene. Clinica Chimica Acta. 2025-01-30, 566 [2024-12-21]. doi:10.1016/j.cca.2024.120059.
Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertility and Sterility. August 2013, 100 (2): 341–8. PMID 23809505. doi:10.1016/j.fertnstert.2013.05.033 .
Hughes E, Brown J, Collins JJ, Vanderkerchove P. Clomiphene citrate for unexplained subfertility in women. The Cochrane Database of Systematic Reviews. January 2010, 2010 (1): CD000057. PMC 7052733 . PMID 20091498. doi:10.1002/14651858.CD000057.pub2.
Powers WJ, Costescu D, Massarella C, Gale J, Singh SS. A Gender-Affirming Approach to Fertility Care for Transgender and Gender-Diverse Patients. (PDF). O&G Open. March 2024, 1 (1): e002 [2024-07-08]. doi:10.1097/og9.0000000000000002.
Schneider F, Neuhaus N, Wistuba J, Zitzmann M, Heß J, Mahler D, van Ahlen H, Schlatt S, Kliesch S. Testicular Functions and Clinical Characterization of Patients with Gender Dysphoria (GD) Undergoing Sex Reassignment Surgery (SRS). The Journal of Sexual Medicine. November 2015, 12 (11): 2190–2200. PMID 26559385. doi:10.1111/jsm.13022.
Bach PV, Najari BB, Kashanian JA. Adjunct Management of Male Hypogonadism. Current Sexual Health Reports. 2016, 8 (4): 231–239. ISSN 1548-3584. S2CID 79220716. doi:10.1007/s11930-016-0089-7.
Wu, Yao-Cheng; Sung, Wen-Wei. Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism: Mechanisms and Clinical Implications. Pharmaceuticals (Basel, Switzerland). 2024-09-18, 17 (9): 1233 [2024-12-21]. doi:10.3390/ph17091233.
Trost LW, Khera M. Alternative treatment modalities for the hypogonadal patient. Current Urology Reports. July 2014, 15 (7): 417. PMID 24817260. S2CID 20304701. doi:10.1007/s11934-014-0417-2.
DiGiorgio L, Sadeghi-Nejad H. Off label therapies for testosterone replacement. Translational Andrology and Urology. December 2016, 5 (6): 844–849. PMC 5182219 . PMID 28078215. doi:10.21037/tau.2016.08.15 .
DiGiorgio, Lorenzo; Sadeghi-Nejad, Hossein. Off label therapies for testosterone replacement. Translational Andrology and Urology. December 2016, 5 (6): 844–849 [2024-12-21]. doi:10.21037/tau.2016.08.15.
Agrawal S, Ganie MA, Nisar S. Gynaecomastia. Basics of Human Andrology. Springer. 2017: 451–458. ISBN 978-981-10-3694-1. doi:10.1007/978-981-10-3695-8_26.
Nordt CA, DiVasta AD. Gynecomastia in adolescents. Current Opinion in Pediatrics. August 2008, 20 (4): 375–82. PMID 18622190. S2CID 205834072. doi:10.1097/MOP.0b013e328306a07c.
Miller GD, Moore C, Nair V, Hill B, Willick SE, Rogol AD, Eichner D. Hypothalamic-Pituitary-Testicular Axis Effects and Urinary Detection Following Clomiphene Administration in Males. The Journal of Clinical Endocrinology and Metabolism. March 2019, 104 (3): 906–914. PMID 30295816. doi:10.1210/jc.2018-01159 .
Garthwaite, Heather; Stewart, Jane. Multiple pregnancy rate in patients undergoing treatment with clomifene citrate for WHO group II ovulatory disorders: a systematic review. Human Fertility (Cambridge, England ). 2021-01-15, 25 (4): 618–624 [2024-12-21]. doi:10.1080/14647273.2021.1872803.
Trabert B, Lamb EJ, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Brinton LA. Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort. Fertility and Sterility. December 2013, 100 (6): 1660–6. PMC 3873340 . PMID 24011610. doi:10.1016/j.fertnstert.2013.08.008.
Gadducci A, Guerrieri ME, Genazzani AR. Fertility drug use and risk of ovarian tumors: a debated clinical challenge. Gynecological Endocrinology. January 2013, 29 (1): 30–5. PMID 22946709. S2CID 1240526. doi:10.3109/09513590.2012.705382.
Yu Q, Lv X, Liu K, Ma D, Wu Y, Dai W, Jiang H. Fertility Drugs Associated with Thyroid Cancer Risk: A Systematic Review and Meta-Analysis. BioMed Research International. 2018, 2018: 7191704. PMC 5971354 . PMID 29862285. doi:10.1155/2018/7191704 .
Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L. A pharmacological review of selective oestrogen receptor modulators. Human Reproduction Update. 2000, 6 (3): 212–24. PMID 10874566. doi:10.1093/humupd/6.3.212 .
Haskell SG. Selective estrogen receptor modulators. Southern Medical Journal. May 2003, 96 (5): 469–76. PMID 12911186. S2CID 40607634. doi:10.1097/01.SMJ.0000051146.93190.4A.
Duarte FH, Jallad RS, Bronstein MD. Estrogens and selective estrogen receptor modulators in acromegaly. Endocrine. November 2016, 54 (2): 306–314. PMID 27704479. S2CID 10136018. doi:10.1007/s12020-016-1118-z.
Obach RS. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy. Pharmacological Reviews. April 2013, 65 (2): 578–640. PMID 23406671. S2CID 720243. doi:10.1124/pr.111.005439.
Rambhatla A, Mills JN, Rajfer J. The Role of Estrogen Modulators in Male Hypogonadism and Infertility. Reviews in Urology. 2016, 18 (2): 66–72. PMC 5010627 . PMID 27601965. doi:10.3909/riu0711 (不活跃 2024-11-01).
Howell A, Jordan VC. Adjuvant Antihormone Therapy. Craig JV (编). Estrogen Action, Selective Estrogen Receptor Modulators And Women's Health: Progress And Promise. World Scientific. 2013: 229–254. ISBN 978-1-84816-959-3. doi:10.1142/9781848169586_0010.
Holtkamp DE, Greslin JG, Root CA, Lerner LJ. Gonadotrophin inhibiting and anti-fecundity effects of chloramiphene. Proceedings of the Society for Experimental Biology and Medicine. October 1960, 105: 197–201. PMID 13715563. S2CID 1448466. doi:10.3181/00379727-105-26054.
Hughes E, Collins J, Vandekerckhove P. Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea. The Cochrane Database of Systematic Reviews. 2000, (2): CD000056. PMID 10796477. doi:10.1002/14651858.CD000056. （已撤稿，见doi:10.1002/14651858.cd000056.pub2)
Palacios S. The future of the new selective estrogen receptor modulators. Menopause International. March 2007, 13 (1): 27–34. PMID 17448265. S2CID 29053109. doi:10.1258/175404507780456791.
Maximov PY, McDaniel RE, Jordan VC. Tamoxifen Goes Forward Alone. Tamoxifen. Milestones in Drug Therapy. Springer. 2013: 31–46. ISBN 978-3-0348-0663-3. ISSN 2296-6064. doi:10.1007/978-3-0348-0664-0_2.

drugs.com

International brands of clomifene -. Drugs.com. [2016-09-11]. （原始内容存档于2016-09-20）.
Clomiphene Citrate. The American Society of Health-System Pharmacists. [8 December 2016]. （原始内容存档于2017-09-14）.
ClomiPHENE (Professional Patient Advice). Drugs.com. [30 July 2019].

espacenet.com

worldwide.espacenet.com

US 2,914,563,Allen RE, Palopoli FP, Schumann EL, Van Campen Jr MG,「Therapeutic composition」,发行于1959-11-24

fda.gov

accessdata.fda.gov

Clomiphene citrate tablets label (PDF). FDA. [2016-09-11]. （原始内容存档 (PDF)于2016-09-27）.

handle.net

hdl.handle.net

World Health Organization. Stuart MC, Kouimtzi M, Hill SR , 编. WHO Model Formulary 2008. World Health Organization. 2009: 385–386. ISBN 9789241547659. hdl:10665/44053 .
World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

hhpronline.org

Adashi EY. Iatrogenic Birth Plurality: The Challenge and Its Possible Solution (PDF). Harvard Health Policy Review. Fall 2014, 14 (1): 9–10 [2016-09-12]. （原始内容 (PDF)存档于2016-10-06）.

latimes.com

Lee P. Dow Chemical to Get Control of Marion Labs : $5-Billion-Plus Deal Is an Effort to Diversify. Los Angeles Times. 1989-07-18. （原始内容存档于2016-06-29）.

lww.com

journals.lww.com

Powers WJ, Costescu D, Massarella C, Gale J, Singh SS. A Gender-Affirming Approach to Fertility Care for Transgender and Gender-Diverse Patients. (PDF). O&G Open. March 2024, 1 (1): e002 [2024-07-08]. doi:10.1097/og9.0000000000000002.

nih.gov

ncbi.nlm.nih.gov

Kim MJ, Byeon JY, Kim YH, Kim SH, Lee CM, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY, Choi CI. Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites. Archives of Pharmacal Research. March 2018, 41 (3): 347–353. PMID 29516347. S2CID 4034257. doi:10.1007/s12272-018-1005-7.
Yilmaz S, Yilmaz Sezer N, Gönenç İM, İlhan SE, Yilmaz E. Safety of clomiphene citrate: a literature review. Cytotechnology. April 2018, 70 (2): 489–495. PMC 5851961 . PMID 29159661. doi:10.1007/s10616-017-0169-1.
Mikkelson TJ, Kroboth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertility and Sterility. September 1986, 46 (3): 392–396. PMID 3091405. doi:10.1016/S0015-0282(16)49574-9.
Dickey RP, Holtkamp DE. Development, pharmacology and clinical experience with clomiphene citrate. Human Reproduction Update. 1996, 2 (6): 483–506. PMID 9111183. doi:10.1093/humupd/2.6.483 .
Rodriguez KM, Pastuszak AW, Lipshultz LI. Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opinion on Pharmacotherapy. August 2016, 17 (11): 1561–7. PMC 5009465 . PMID 27337642. doi:10.1080/14656566.2016.1204294.
Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertility and Sterility. August 2013, 100 (2): 341–8. PMID 23809505. doi:10.1016/j.fertnstert.2013.05.033 .
Hughes E, Brown J, Collins JJ, Vanderkerchove P. Clomiphene citrate for unexplained subfertility in women. The Cochrane Database of Systematic Reviews. January 2010, 2010 (1): CD000057. PMC 7052733 . PMID 20091498. doi:10.1002/14651858.CD000057.pub2.
Schneider F, Neuhaus N, Wistuba J, Zitzmann M, Heß J, Mahler D, van Ahlen H, Schlatt S, Kliesch S. Testicular Functions and Clinical Characterization of Patients with Gender Dysphoria (GD) Undergoing Sex Reassignment Surgery (SRS). The Journal of Sexual Medicine. November 2015, 12 (11): 2190–2200. PMID 26559385. doi:10.1111/jsm.13022.
Trost LW, Khera M. Alternative treatment modalities for the hypogonadal patient. Current Urology Reports. July 2014, 15 (7): 417. PMID 24817260. S2CID 20304701. doi:10.1007/s11934-014-0417-2.
DiGiorgio L, Sadeghi-Nejad H. Off label therapies for testosterone replacement. Translational Andrology and Urology. December 2016, 5 (6): 844–849. PMC 5182219 . PMID 28078215. doi:10.21037/tau.2016.08.15 .
Nordt CA, DiVasta AD. Gynecomastia in adolescents. Current Opinion in Pediatrics. August 2008, 20 (4): 375–82. PMID 18622190. S2CID 205834072. doi:10.1097/MOP.0b013e328306a07c.
Miller GD, Moore C, Nair V, Hill B, Willick SE, Rogol AD, Eichner D. Hypothalamic-Pituitary-Testicular Axis Effects and Urinary Detection Following Clomiphene Administration in Males. The Journal of Clinical Endocrinology and Metabolism. March 2019, 104 (3): 906–914. PMID 30295816. doi:10.1210/jc.2018-01159 .
Trabert B, Lamb EJ, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Brinton LA. Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort. Fertility and Sterility. December 2013, 100 (6): 1660–6. PMC 3873340 . PMID 24011610. doi:10.1016/j.fertnstert.2013.08.008.
Gadducci A, Guerrieri ME, Genazzani AR. Fertility drug use and risk of ovarian tumors: a debated clinical challenge. Gynecological Endocrinology. January 2013, 29 (1): 30–5. PMID 22946709. S2CID 1240526. doi:10.3109/09513590.2012.705382.
Yu Q, Lv X, Liu K, Ma D, Wu Y, Dai W, Jiang H. Fertility Drugs Associated with Thyroid Cancer Risk: A Systematic Review and Meta-Analysis. BioMed Research International. 2018, 2018: 7191704. PMC 5971354 . PMID 29862285. doi:10.1155/2018/7191704 .
Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L. A pharmacological review of selective oestrogen receptor modulators. Human Reproduction Update. 2000, 6 (3): 212–24. PMID 10874566. doi:10.1093/humupd/6.3.212 .
Haskell SG. Selective estrogen receptor modulators. Southern Medical Journal. May 2003, 96 (5): 469–76. PMID 12911186. S2CID 40607634. doi:10.1097/01.SMJ.0000051146.93190.4A.
Duarte FH, Jallad RS, Bronstein MD. Estrogens and selective estrogen receptor modulators in acromegaly. Endocrine. November 2016, 54 (2): 306–314. PMID 27704479. S2CID 10136018. doi:10.1007/s12020-016-1118-z.
Obach RS. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy. Pharmacological Reviews. April 2013, 65 (2): 578–640. PMID 23406671. S2CID 720243. doi:10.1124/pr.111.005439.
Rambhatla A, Mills JN, Rajfer J. The Role of Estrogen Modulators in Male Hypogonadism and Infertility. Reviews in Urology. 2016, 18 (2): 66–72. PMC 5010627 . PMID 27601965. doi:10.3909/riu0711 (不活跃 2024-11-01).
Jensen EV, Jordan VC (June 2003). "The estrogen receptor: a model for molecular medicine". Clin. Cancer Res. 9 (6): 1980–9. PMID 12796359.
Holtkamp DE, Greslin JG, Root CA, Lerner LJ. Gonadotrophin inhibiting and anti-fecundity effects of chloramiphene. Proceedings of the Society for Experimental Biology and Medicine. October 1960, 105: 197–201. PMID 13715563. S2CID 1448466. doi:10.3181/00379727-105-26054.
Hughes E, Collins J, Vandekerckhove P. Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea. The Cochrane Database of Systematic Reviews. 2000, (2): CD000056. PMID 10796477. doi:10.1002/14651858.CD000056. （已撤稿，见doi:10.1002/14651858.cd000056.pub2)
Palacios S. The future of the new selective estrogen receptor modulators. Menopause International. March 2007, 13 (1): 27–34. PMID 17448265. S2CID 29053109. doi:10.1258/175404507780456791.

pubmed.ncbi.nlm.nih.gov

Wu, Yao-Cheng; Sung, Wen-Wei. Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism: Mechanisms and Clinical Implications. Pharmaceuticals (Basel, Switzerland). 2024-09-18, 17 (9): 1233 [2024-12-21]. doi:10.3390/ph17091233.
Garthwaite, Heather; Stewart, Jane. Multiple pregnancy rate in patients undergoing treatment with clomifene citrate for WHO group II ovulatory disorders: a systematic review. Human Fertility (Cambridge, England ). 2021-01-15, 25 (4): 618–624 [2024-12-21]. doi:10.1080/14647273.2021.1872803.

pmc.ncbi.nlm.nih.gov

DiGiorgio, Lorenzo; Sadeghi-Nejad, Hossein. Off label therapies for testosterone replacement. Translational Andrology and Urology. December 2016, 5 (6): 844–849 [2024-12-21]. doi:10.21037/tau.2016.08.15.

nytimes.com

Williams W. Dow Broadens Product Lines. The New York Times. 1981-02-11. ISSN 0362-4331. （原始内容存档于2016-10-06）.
Timmons H, Bennhold K. France Helped Broker the Aventis-Sanofi Deal. The New York Times. 2004-04-27. （原始内容存档于2017-11-05）.

psu.edu

citeseerx.ist.psu.edu

Arturo Bris and Christos Cabolis, Corporate Governance Convergence Through Cross-Border Mergers The Case of Aventis 互联网档案馆的存檔，存档日期2014-04-21., Chapter 4 in Corporate Governance and Regulatory Impact on Mergers and Acquisitions: Research and Analysis on Activity Worldwide Since 1990. Eds Greg N. Gregoriou, Luc Renneboog. Academic Press, 2007-07-26

sciencedirect.com

Kintz, Pascal; Gheddar, Laurie. Interest of hair tests and supplement tests to discriminate a tail end of a doping regimen from a supplement contamination in case of challenging an anti-doping rule violation. VII. Case example with clomiphene. Clinica Chimica Acta. 2025-01-30, 566 [2024-12-21]. doi:10.1016/j.cca.2024.120059.

semanticscholar.org

api.semanticscholar.org

Kim MJ, Byeon JY, Kim YH, Kim SH, Lee CM, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY, Choi CI. Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites. Archives of Pharmacal Research. March 2018, 41 (3): 347–353. PMID 29516347. S2CID 4034257. doi:10.1007/s12272-018-1005-7.
Bach PV, Najari BB, Kashanian JA. Adjunct Management of Male Hypogonadism. Current Sexual Health Reports. 2016, 8 (4): 231–239. ISSN 1548-3584. S2CID 79220716. doi:10.1007/s11930-016-0089-7.
Trost LW, Khera M. Alternative treatment modalities for the hypogonadal patient. Current Urology Reports. July 2014, 15 (7): 417. PMID 24817260. S2CID 20304701. doi:10.1007/s11934-014-0417-2.
Nordt CA, DiVasta AD. Gynecomastia in adolescents. Current Opinion in Pediatrics. August 2008, 20 (4): 375–82. PMID 18622190. S2CID 205834072. doi:10.1097/MOP.0b013e328306a07c.
Gadducci A, Guerrieri ME, Genazzani AR. Fertility drug use and risk of ovarian tumors: a debated clinical challenge. Gynecological Endocrinology. January 2013, 29 (1): 30–5. PMID 22946709. S2CID 1240526. doi:10.3109/09513590.2012.705382.
Haskell SG. Selective estrogen receptor modulators. Southern Medical Journal. May 2003, 96 (5): 469–76. PMID 12911186. S2CID 40607634. doi:10.1097/01.SMJ.0000051146.93190.4A.
Duarte FH, Jallad RS, Bronstein MD. Estrogens and selective estrogen receptor modulators in acromegaly. Endocrine. November 2016, 54 (2): 306–314. PMID 27704479. S2CID 10136018. doi:10.1007/s12020-016-1118-z.
Obach RS. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy. Pharmacological Reviews. April 2013, 65 (2): 578–640. PMID 23406671. S2CID 720243. doi:10.1124/pr.111.005439.
Holtkamp DE, Greslin JG, Root CA, Lerner LJ. Gonadotrophin inhibiting and anti-fecundity effects of chloramiphene. Proceedings of the Society for Experimental Biology and Medicine. October 1960, 105: 197–201. PMID 13715563. S2CID 1448466. doi:10.3181/00379727-105-26054.
Palacios S. The future of the new selective estrogen receptor modulators. Menopause International. March 2007, 13 (1): 27–34. PMID 17448265. S2CID 29053109. doi:10.1258/175404507780456791.

sfgate.com

Hoechst AG to Buy Marion Merrell Dow / Acquisition worth over $7 billion. San Francisco Chronicle. Reuters. 1995-05-05. （原始内容存档于2016-10-06）.

uptodate.com

Seli E, Arici A. Ovulation induction with clomiphene citrate. UpToDate. [2019-07-30].

usada.org

Substance Profile: What Athletes Need to Know about Clomiphene. USADA. [2024-12-22].
Substance Profile: What Athletes Need to Know About Clomiphene. USADA. 2017-02-02.

wada-main-prod.s3.amazonaws.com

The WADA Prohibited List 2016 (listed as clomiphene) 互联网档案馆的存檔，存档日期6 March 2016.

web.archive.org

International brands of clomifene -. Drugs.com. [2016-09-11]. （原始内容存档于2016-09-20）.
Clomiphene Citrate. The American Society of Health-System Pharmacists. [8 December 2016]. （原始内容存档于2017-09-14）.
Clomiphene citrate tablets label (PDF). FDA. [2016-09-11]. （原始内容存档 (PDF)于2016-09-27）.
Ghumman S. Principles and Practice of Controlled Ovarian Stimulation in ART. Springer. 2015: 65. ISBN 9788132216865. （原始内容存档于2016-12-27）.
Analytical Profiles of Drug Substances and Excipients. Academic Press. 1998-03-20: 113–. ISBN 978-0-08-086120-3. （原始内容存档于2017-11-05）.
Adashi EY. Iatrogenic Birth Plurality: The Challenge and Its Possible Solution (PDF). Harvard Health Policy Review. Fall 2014, 14 (1): 9–10 [2016-09-12]. （原始内容 (PDF)存档于2016-10-06）.
Lee P. Dow Chemical to Get Control of Marion Labs : $5-Billion-Plus Deal Is an Effort to Diversify. Los Angeles Times. 1989-07-18. （原始内容存档于2016-06-29）.
Williams W. Dow Broadens Product Lines. The New York Times. 1981-02-11. ISSN 0362-4331. （原始内容存档于2016-10-06）.
Hoechst AG to Buy Marion Merrell Dow / Acquisition worth over $7 billion. San Francisco Chronicle. Reuters. 1995-05-05. （原始内容存档于2016-10-06）.
Arturo Bris and Christos Cabolis, Corporate Governance Convergence Through Cross-Border Mergers The Case of Aventis 互联网档案馆的存檔，存档日期2014-04-21., Chapter 4 in Corporate Governance and Regulatory Impact on Mergers and Acquisitions: Research and Analysis on Activity Worldwide Since 1990. Eds Greg N. Gregoriou, Luc Renneboog. Academic Press, 2007-07-26
Timmons H, Bennhold K. France Helped Broker the Aventis-Sanofi Deal. The New York Times. 2004-04-27. （原始内容存档于2017-11-05）.
Strauss JF, Barbieri RL. Yen and Jaffe's Reproductive Endocrinology. Elsevier Health Sciences. 2013-09-13: 518–. ISBN 978-1-4557-2758-2. （原始内容存档于2017-11-05）.
The WADA Prohibited List 2016 (listed as clomiphene) 互联网档案馆的存檔，存档日期6 March 2016.
Hormones and Breast Cancer. Elsevier. 2013-06-25: 13–. ISBN 978-0-12-416676-9. （原始内容存档于2017-11-05）.

worldcat.org

Bach PV, Najari BB, Kashanian JA. Adjunct Management of Male Hypogonadism. Current Sexual Health Reports. 2016, 8 (4): 231–239. ISSN 1548-3584. S2CID 79220716. doi:10.1007/s11930-016-0089-7.
Williams W. Dow Broadens Product Lines. The New York Times. 1981-02-11. ISSN 0362-4331. （原始内容存档于2016-10-06）.
Maximov PY, McDaniel RE, Jordan VC. Tamoxifen Goes Forward Alone. Tamoxifen. Milestones in Drug Therapy. Springer. 2013: 31–46. ISBN 978-3-0348-0663-3. ISSN 2296-6064. doi:10.1007/978-3-0348-0664-0_2.